D. E. Shaw & Co., Inc. Design Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 390,648 shares of DSGN stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
390,648
Previous 395,251
1.16%
Holding current value
$2.28 Million
Previous $1.53 Million
13.7%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding DSGN
# of Institutions
95Shares Held
33.5MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$38 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$24.6 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$13.4 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$11.4 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$10.5 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $325M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...